Vasculitis & polymyalgia rheumatica
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
Authors' conclusion
There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR.
Study context
- Population
- Publications providing clinical descriptions and domains of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis and ICI-induced PMR (Medline, EMBASE, Cochrane, CINHL through March 2021)69 publications
- Outcome
- Clinical descriptors and outcome domains used for ICI-induced IA and ICI-induced PMR, mapped to OMERACT core areas
Methodological detailsOMERACT 2.1 Filter mapping of domains to core areas
- OMERACT 2.1 Filter mapping of domains to core areas
Main finding
As reported in the abstract
- Publications identified
- 69
- Domains mapped to pathophysiology/manifestations core area
- 24
- Signs/symptoms domains
- 13
- Lab domains
- 6
- Imaging domains
- 5
- Publications referencing irAE treatment
- 43
- Publications referencing subsequent response
- 35
- Publications referencing tumor response
- 32
Original publication
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Semin Arthritis Rheum. Published 26 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →